We included traditional risk factors and their treatment (Table 2), the presence of the most prevalent autoantibodies (ANA, anti-Jo-1, and anti-Ro-52), clinical features [Raynaud's phenomenon (RP), mechanic's hands (MH) and ILD], and pharmacotherapy (GC, MTX, and AZA) (Table 9). This evidence concerns the gene TRIM21 and interstitial lung disease.